Full-Time

Senior Data Engineer

Data Engineering

Posted on 7/11/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (1)
Required Skills
Microsoft Azure
Agile
Python
Data Science
Apache Spark
SQL
Apache Kafka
AWS
JIRA
Confluence
DevOps
Databricks
Google Cloud Platform
Requirements
  • Build and maintain data pipelines to ingest and update metadata into enterprise data catalog platforms in biotech or life sciences or pharma.
  • Hands-on experience in data engineering technologies such as Databricks, PySpark, SparkSQL Apache Spark, AWS, Python, SQL, and Scaled Agile methodologies.
  • Proficiency in workflow orchestration, performance tuning on big data processing.
  • Experience in data engineering, data operations, or related roles, with at least 2+ years in life sciences, biotech, or pharmaceutical environments.
  • Experience with cloud platforms (e.g., AWS, Azure, or GCP) for data pipeline and storage solutions.
  • Understanding of data governance frameworks, metadata management, and data lineage tracking.
  • Strong problem-solving skills, attention to detail, and ability to manage multiple priorities in a dynamic environment.
  • Effective communication and collaboration skills to work across technical and business stakeholders.
  • Strong problem-solving and analytical skills
  • Excellent communication and teamwork skills
  • Experience with Scaled Agile Framework (SAFe), Agile delivery practices, and DevOps practices.
Responsibilities
  • Design, build, and support data ingestion, transformation, and delivery pipelines across structured and unstructured sources within the enterprise data engineering.
  • Manage and monitor day-to-day operations of the data engineering environment, ensuring high availability, performance, and data integrity.
  • Collaborate with data architects, data governance, platform engineering, and business teams to support data integration use cases across R&D, Clinical, Regulatory, and Commercial functions.
  • Integrate data from laboratory systems, clinical platforms, regulatory systems, and third-party data sources into enterprise data repositories.
  • Implement and maintain metadata capture, data lineage, and data quality checks across pipelines to meet governance and compliance requirements.
  • Support real-time and batch data flows using technologies such as Databricks, Kafka, Delta Lake, or similar.
  • Work within GxP-aligned environments, ensuring compliance with data privacy, audit, and quality control standards.
  • Partner with data stewards and business analysts to support self-service data access, reporting, and analytics enablement.
  • Maintain operational documentation, runbooks, and process automation scripts for continuous improvement of data fabric operations.
  • Participate in incident resolution and root cause analysis, ensuring timely and effective remediation of data pipeline issues.
  • Create documentation, playbooks, and best practices for metadata ingestion, data lineage, and catalog usage.
  • Work in an Agile and Scaled Agile (SAFe) environment, collaborating with cross-functional teams, product owners, and Scrum Masters to deliver incremental value
  • Use JIRA, Confluence, and Agile DevOps tools to manage sprints, backlogs, and user stories.
  • Support continuous improvement, test automation, and DevOps practices in the data engineering lifecycle
  • Collaborate and communicate effectively with the product teams, with cross-functional teams to understand business requirements and translate them into technical solutions.
Desired Qualifications
  • Data Engineering experience in Biotechnology or pharma industry
  • Experience in writing APIs to make the data available to the consumers
  • Experienced with SQL/NOSQL database, vector database for large language models
  • Experienced with data modeling and performance tuning for both OLAP and OLTP databases
  • Experienced with software engineering best-practices, including but not limited to version control (Git, Subversion, etc.), CI/CD (Jenkins, Maven etc.), automated unit testing, and Dev Ops

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • MariTide's four-to-six-dose regimen could improve adherence and support obesity launch uptake.
  • IMDYLLTRA's Phase 3 survival benefit strengthens Amgen's oncology pipeline and commercial credibility.
  • Repatha growth, strong free cash flow, and AI efficiency support margin expansion.[1]

What critics are saying

  • Prolia's declining sales expose Amgen to erosion in its mature osteoporosis franchise.
  • MariTide still faces Phase 3, manufacturing, and tolerability execution risk before launch.
  • Tavneos regulatory scrutiny and tarlatamab safety concerns can limit near-term revenue conversion.

What makes Amgen unique

  • Amgen spans oncology, inflammation, rare disease, and general medicine across 100 countries.[1][3]
  • It combines biologics manufacturing with AI-driven discovery and development workflows.[1][5]
  • MariTide and IMDYLLTRA give Amgen distinct obesity and small-cell lung cancer growth options.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE